top of page

About Us
Amytrx is a clinical-stage biopharmaceutical company advancing the next generation of new anti-inflammatory peptide therapies for patients suffering from chronic inflammatory diseases. We are a group of dedicated scientific, medical, and business professionals all deeply committed to positively transforming the health and lives of patients.
Leadership Team

Matthew A. Gonda, Ph.D.
President, CEO and Founder

Randall B. Riggs, MBA
Chief Business Officer

Shima Joshi, Ph.D.
VP, Regulatory Affairs

Vernon L. Alvarez, Ph.D.
SVP, Research & Development

Satish Joshi, Ph.D.
VP, Peptide Chemistry

Danny O. Helton, Ph.D.
VP, Chemistry & Manufacturing
Board of Directors
Matthew A. Gonda, Ph.D.
President, CEO and Founder
Lawrence W. Greer, DDS, MBA
Director
G. William Coble, II
Director
Daniel D. Canale, M.D.
Director
Thomas G. Andrews
Director and Founder
Dennis J. Carlo, Ph.D.
Director
Raymond Pirtle, Jr.
Director
bottom of page